Segment information

9 Months Ended

Sep. 30, 2012

Segment information [Abstract]

Segment information

12.  Segment information

For financial reporting purposes, the Company reports financial information for two business segments: Biodefense and Biosciences. The Company's two business segments, or divisions, engage in business activities for which discrete financial information is reviewed by the chief operating decision maker. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies. The Company's reportable segments are business units that offer different products and product candidates and are managed separately because they manufacture and develop distinct products with different development processes.

In the Biodefense division, the Company develops, manufactures and commercializes vaccines and antibody therapies for use against biological agents that are potential weapons of bioterrorism. Revenues in this segment are primarily from sales of the Company's FDA-licensed product, BioThrax® (Anthrax Vaccine Adsorbed), to the U.S. government. In the Biosciences division, the Company develops vaccines, protein therapeutics and technology platforms for use against infectious diseases, oncology, autoimmune and inflammatory disorders and other medical conditions that have resulted in significant unmet or underserved public health needs.  The Biosciences division consists of two business units, therapeutics and vaccines, and is comprised of development stage product candidates. The "All Other" segment relates to the general operating costs of the Company and includes costs of the centralized services departments, which are not allocated to the other segments, as well as spending on activities that are not classified as Biodefense or Biosciences. The assets in this segment consist primarily of cash.

The Company's segment presentation for the three and nine months ended September 30, 2011 has been reclassified to conform to the 2012 presentation.  In the third quarter of 2012, the Company received a contract from the U.S. government to establish a Center for Innovation in Advanced Development and Manufacturing and as such reevaluated its segments. The Company reclassified certain components of its segments to reflect the current presentation to, and review of, financial information by the chief operating decision maker. Total assets by reportable segments are not disclosed as these assets are not reviewed separately by the Company's chief operating decision maker.

	Reportable Segments
(in thousands)	Biodefense		Biosciences			All Other			Total
Three Months Ended September 30, 2012
External revenue	$	66,238	$	354		$	-		$	66,592
Net income (loss)		20,760		(12,165	)		(1,978	)		6,617
Three Months Ended September 30, 2011
External revenue	$	56,679	$	2,083		$	-		$	58,762
Net income (loss)		17,326		(14,260	)		(1,517	)		1,549

	Reportable Segments
(in thousands)	Biodefense		Biosciences			All Other			Total
Nine Months Ended September 30, 2012
External revenue	$	181,838	$	5,444		$	-		$	187,282
Net income (loss)		59,361		(47,019	)		(4,925	)		7,417
Nine Months Ended September 30, 2011
External revenue	$	155,864	$	9,572		$	-		$	165,436
Net income (loss)		46,863		(48,691	)		(3,810	)		(5,638	)